Insulin degludec is a new ultra-long-acting insulin analogue

Achieving optimal glycemic control is an important aspect of preventing and slowing the progression of diabetes-associated complications, and reducing the cost of their treatment. Long-acting insulin analogues, glargine and detemir, provide better metabolic control with reduced risk of hypoglycaemia...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ivan Ivanovich Dedov, Marina Vladimirovna Shestakova
Formato:	article
Lenguaje:	EN RU
Publicado:	Endocrinology Research Centre 2014
Materias:	diabetes mellitus, glycemic control basal insulin degludec hypoglycaemia Nutritional diseases. Deficiency diseases RC620-627
Acceso en línea:	https://doaj.org/article/6e417b1bfcf04a568b284fe7ce6e9f5f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6e417b1bfcf04a568b284fe7ce6e9f5f
record_format	dspace
spelling	oai:doaj.org-article:6e417b1bfcf04a568b284fe7ce6e9f5f2021-11-14T09:00:19ZInsulin degludec is a new ultra-long-acting insulin analogue2072-03512072-037810.14341/DM2014291-104https://doaj.org/article/6e417b1bfcf04a568b284fe7ce6e9f5f2014-07-01T00:00:00Zhttps://www.dia-endojournals.ru/jour/article/view/6605https://doaj.org/toc/2072-0351https://doaj.org/toc/2072-0378Achieving optimal glycemic control is an important aspect of preventing and slowing the progression of diabetes-associated complications, and reducing the cost of their treatment. Long-acting insulin analogues, glargine and detemir, provide better metabolic control with reduced risk of hypoglycaemia as compared to NPH insulin. However, fear of hypoglycaemia and weight gain, as well as the complexity of regimen, are still the most important barriers to well-timed initiation and intensification of insulin therapy. Insulin degludec (Tresiba?) is a new ultra-long-acting insulin analogue. After subcutaneous injection degludec forms repository of soluble multi-hexamers, which are gradually absorbed to the bloodstream, providing a flat, stable antihyperglycemic effect lasting more than 42 h, and low intra-individual variability as opposed to currently used basal insulin analogues, insulin glargine and insulin detemir. In the seven randomized, open label, controlled phase 3 trials lasting 26 or 52 weeks, using treat-to-target (no more) non-inferiority design, insulin degludec provided glycemic control similar to that of insulin glargine with lower risk of nocturnal hypoglycaemia and good safety profile in patients with type 1 or 2 diabetes. Furthermore, trials examining a flexible dosing regimen of insulin degludec in patients with type 1 or 2 diabetes have shown that it is possible to vary the injection time without compromising glycemic control or safety of the therapy.Ivan Ivanovich DedovMarina Vladimirovna ShestakovaEndocrinology Research Centrearticlediabetes mellitus, glycemic controlbasal insulindegludechypoglycaemiaNutritional diseases. Deficiency diseasesRC620-627ENRUСахарный диабет, Vol 17, Iss 2, Pp 91-104 (2014)
institution	DOAJ
collection	DOAJ
language	EN RU
topic	diabetes mellitus, glycemic control basal insulin degludec hypoglycaemia Nutritional diseases. Deficiency diseases RC620-627
spellingShingle	diabetes mellitus, glycemic control basal insulin degludec hypoglycaemia Nutritional diseases. Deficiency diseases RC620-627 Ivan Ivanovich Dedov Marina Vladimirovna Shestakova Insulin degludec is a new ultra-long-acting insulin analogue
description	Achieving optimal glycemic control is an important aspect of preventing and slowing the progression of diabetes-associated complications, and reducing the cost of their treatment. Long-acting insulin analogues, glargine and detemir, provide better metabolic control with reduced risk of hypoglycaemia as compared to NPH insulin. However, fear of hypoglycaemia and weight gain, as well as the complexity of regimen, are still the most important barriers to well-timed initiation and intensification of insulin therapy. Insulin degludec (Tresiba?) is a new ultra-long-acting insulin analogue. After subcutaneous injection degludec forms repository of soluble multi-hexamers, which are gradually absorbed to the bloodstream, providing a flat, stable antihyperglycemic effect lasting more than 42 h, and low intra-individual variability as opposed to currently used basal insulin analogues, insulin glargine and insulin detemir. In the seven randomized, open label, controlled phase 3 trials lasting 26 or 52 weeks, using treat-to-target (no more) non-inferiority design, insulin degludec provided glycemic control similar to that of insulin glargine with lower risk of nocturnal hypoglycaemia and good safety profile in patients with type 1 or 2 diabetes. Furthermore, trials examining a flexible dosing regimen of insulin degludec in patients with type 1 or 2 diabetes have shown that it is possible to vary the injection time without compromising glycemic control or safety of the therapy.
format	article
author	Ivan Ivanovich Dedov Marina Vladimirovna Shestakova
author_facet	Ivan Ivanovich Dedov Marina Vladimirovna Shestakova
author_sort	Ivan Ivanovich Dedov
title	Insulin degludec is a new ultra-long-acting insulin analogue
title_short	Insulin degludec is a new ultra-long-acting insulin analogue
title_full	Insulin degludec is a new ultra-long-acting insulin analogue
title_fullStr	Insulin degludec is a new ultra-long-acting insulin analogue
title_full_unstemmed	Insulin degludec is a new ultra-long-acting insulin analogue
title_sort	insulin degludec is a new ultra-long-acting insulin analogue
publisher	Endocrinology Research Centre
publishDate	2014
url	https://doaj.org/article/6e417b1bfcf04a568b284fe7ce6e9f5f
work_keys_str_mv	AT ivanivanovichdedov insulindegludecisanewultralongactinginsulinanalogue AT marinavladimirovnashestakova insulindegludecisanewultralongactinginsulinanalogue
_version_	1718429536383664128

Insulin degludec is a new ultra-long-acting insulin analogue

Ejemplares similares